SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX
Delisted
SGTX was delisted on the 10th of August, 2023.
48 hedge funds and large institutions have $26.8M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
62% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 21
Holders
48
Holding in Top 10
–
Calls
$44K
Puts
$2K
Top Buyers
| 1 | +$230K | |
| 2 | +$102K | |
| 3 | +$19.1K | |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$16K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.7K |
Top Sellers
| 1 | -$498K | |
| 2 | -$394K | |
| 3 | -$322K | |
| 4 |
Millennium Management
New York
|
-$103K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$80K |